SG11202007688YA - Toll-like receptor ligands - Google Patents
Toll-like receptor ligandsInfo
- Publication number
- SG11202007688YA SG11202007688YA SG11202007688YA SG11202007688YA SG11202007688YA SG 11202007688Y A SG11202007688Y A SG 11202007688YA SG 11202007688Y A SG11202007688Y A SG 11202007688YA SG 11202007688Y A SG11202007688Y A SG 11202007688YA SG 11202007688Y A SG11202007688Y A SG 11202007688YA
- Authority
- SG
- Singapore
- Prior art keywords
- toll
- receptor ligands
- ligands
- receptor
- Prior art date
Links
- 102000002689 Toll-like receptor Human genes 0.000 title 1
- 108020000411 Toll-like receptor Proteins 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/14—Acyclic radicals, not substituted by cyclic structures attached to a sulfur, selenium or tellurium atom of a saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862629513P | 2018-02-12 | 2018-02-12 | |
PCT/US2019/017669 WO2019157509A1 (en) | 2018-02-12 | 2019-02-12 | Toll-like receptor ligands |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202007688YA true SG11202007688YA (en) | 2020-09-29 |
Family
ID=67548588
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202007688YA SG11202007688YA (en) | 2018-02-12 | 2019-02-12 | Toll-like receptor ligands |
Country Status (12)
Country | Link |
---|---|
US (2) | US11458151B2 (ko) |
EP (1) | EP3752182B1 (ko) |
JP (2) | JP7362667B2 (ko) |
KR (1) | KR20200123436A (ko) |
AU (1) | AU2019218978A1 (ko) |
BR (1) | BR112020016314A2 (ko) |
CA (1) | CA3090271A1 (ko) |
EA (1) | EA202091931A1 (ko) |
IL (1) | IL276608B2 (ko) |
MX (1) | MX2020008417A (ko) |
SG (1) | SG11202007688YA (ko) |
WO (1) | WO2019157509A1 (ko) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022534038A (ja) | 2019-05-23 | 2022-07-27 | ザ ユニバーシティー オブ モンタナ | Tlr受容体リガンドをベースとするワクチンアジュバント |
CN116056721A (zh) * | 2020-06-22 | 2023-05-02 | 住友制药株式会社 | 具有tlr4激动剂活性的佐剂 |
JP2023542141A (ja) | 2020-09-15 | 2023-10-05 | ザ ユニバーシティー オブ モンタナ | 繊維状バクテリオファージを標的化する組成物および方法 |
US20230398211A1 (en) | 2020-10-28 | 2023-12-14 | Sanofi Pasteur | Liposomes Containing TLR4 Agonist, Preparation and Uses Thereof |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61126094A (ja) * | 1984-11-26 | 1986-06-13 | Toho Yakuhin Kogyo Kk | リピドaの非還元側サブユニツト類縁体 |
JPS63179885A (ja) * | 1985-12-06 | 1988-07-23 | Ono Pharmaceut Co Ltd | 新規なグリコピラノース誘導体 |
US5530113A (en) | 1991-10-11 | 1996-06-25 | Eisai Co., Ltd. | Anti-endotoxin compounds |
BR9408071A (pt) | 1993-11-17 | 1996-12-24 | Om Lab Sa | Di-sacarideos de glucosamina processo para sua preparação e composição farmacêutica que compreende os mesmos e seu uso |
JP2000511769A (ja) | 1996-04-02 | 2000-09-12 | スミスクライン・ビーチャム・コーポレイション | 新規化合物 |
EP0914330A4 (en) | 1996-05-14 | 2002-01-09 | Smithkline Beecham Corp | NEW TYPE COMPOUNDS |
EP1400592A1 (en) | 1996-10-31 | 2004-03-24 | Human Genome Sciences, Inc. | Streptococcus pneumoniae polynucleotides and sequences |
US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
US6764840B2 (en) | 1997-05-08 | 2004-07-20 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
US6355257B1 (en) | 1997-05-08 | 2002-03-12 | Corixa Corporation | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
US7063967B2 (en) | 1997-05-08 | 2006-06-20 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
US7541020B2 (en) | 1997-05-08 | 2009-06-02 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
US6800744B1 (en) | 1997-07-02 | 2004-10-05 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics |
JP4472866B2 (ja) | 1997-11-06 | 2010-06-02 | カイロン ソチエタ ア レスポンサビリタ リミタータ | ナイセリア抗原 |
EP1034277B1 (en) | 1997-11-26 | 2012-06-27 | Inhibitex, Inc. | Extracellular matrix-binding proteins from Staphylococcus aureus |
ES2333071T5 (es) | 1998-01-14 | 2015-08-17 | Novartis Vaccines And Diagnostics S.R.L. | Antígenos de Neisseria meningitidis |
CA2328399A1 (en) | 1998-04-23 | 1999-10-28 | University Of Alabama At Birmingham | Pneumococcal surface protein c(pspc), epitopic regions and strain selection thereof, and uses therefor |
ES2294629T3 (es) | 1998-05-01 | 2008-04-01 | Novartis Vaccines And Diagnostics, Inc. | Antigenos de neisseria y composiciones. |
GB9810193D0 (en) | 1998-05-12 | 1998-07-08 | Smithkline Beecham Biolog | Novel compounds |
WO1999065480A1 (fr) * | 1998-06-16 | 1999-12-23 | Ono Pharmaceutical Co., Ltd. | Derives de glucopyranose et agents preventifs et/ou remedes contre l'infection a vih, contenant lesdits derives sous forme principe actif |
DE69935986D1 (de) | 1998-07-27 | 2007-06-14 | Sanofi Pasteur Ltd | Streptococcus pneumoniae proteine und nukleinsäuren |
JP2002521058A (ja) | 1998-07-27 | 2002-07-16 | マイクロビアル テクニクス リミティッド | 肺炎連鎖球菌由来の核酸及びタンパク質 |
CN1283798C (zh) | 1998-08-31 | 2006-11-08 | 都柏林伊丽莎白女皇神学院 | 凝固酶阴性葡萄球菌的多肽及多核苷酸 |
CA2340304C (en) | 1998-08-31 | 2012-12-04 | Inhibitex, Inc. | Multicomponent vaccines |
GB9828000D0 (en) | 1998-12-18 | 1999-02-10 | Chiron Spa | Antigens |
AU776828B2 (en) | 1998-12-21 | 2004-09-23 | Medimmune, Llc | Streptococcus pneumoniae proteins and immunogenic fragments for vaccines |
CN1198932C (zh) | 1999-03-26 | 2005-04-27 | 科特克斯(Om)有限公司 | 肺炎链球菌抗原 |
ATE500843T1 (de) | 1999-06-10 | 2011-03-15 | Medimmune Llc | Streptococcus pneumoniae proteine und impfstoffe |
EP1075841A1 (en) | 1999-08-13 | 2001-02-14 | Erasmus Universiteit Rotterdam | Pneumococcal vaccines |
US6699846B2 (en) | 2000-03-17 | 2004-03-02 | Corixa Corporation | Mono- and disaccharides for the treatment of nitric oxide related disorders |
AU2001249345A1 (en) | 2000-03-21 | 2001-10-03 | Elitra Pharmaceuticals, Inc. | Identification of essential genes in prokaryotes |
EP1278856A2 (en) | 2000-04-27 | 2003-01-29 | Medimmune, Inc. | Immunogenic pneumococcal protein and vaccine compositions thereof |
US20030105032A1 (en) | 2000-05-19 | 2003-06-05 | Persing David H. | Phophylactic and therapeutic treatment of infectious and other diseases with mono-and disaccharide-based compounds |
US20030139356A1 (en) | 2001-05-18 | 2003-07-24 | Persing David H. | Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds |
AU6969501A (en) | 2000-05-19 | 2001-12-03 | Corixa Corp | Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds |
DE60139690D1 (de) | 2000-07-03 | 2009-10-08 | Novartis Vaccines & Diagnostic | Immunisierung gegen chlamydia pneumoniae |
US20040091495A1 (en) | 2000-07-20 | 2004-05-13 | Lars Bjorck | Protein |
DE60118207T2 (de) | 2000-08-04 | 2006-11-09 | Corixa Corp., Seattle | Neue immunoeffectorverbindungen |
AU8743001A (en) | 2000-08-28 | 2002-03-13 | Aventis Pasteur | Moraxella polypeptides and corresponding dna fragments and uses thereof |
PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
GB0022742D0 (en) | 2000-09-15 | 2000-11-01 | Smithkline Beecham Biolog | Vaccine |
CA2426738A1 (en) | 2000-10-26 | 2002-05-02 | David William Holden | Streptococcal genes |
EP2277894A1 (en) | 2000-10-27 | 2011-01-26 | Novartis Vaccines and Diagnostics S.r.l. | Nucleic acids and proteins from streptococcus groups A & B |
AT410798B (de) | 2001-01-26 | 2003-07-25 | Cistem Biotechnologies Gmbh | Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen |
GB0103424D0 (en) | 2001-02-12 | 2001-03-28 | Chiron Spa | Gonococcus proteins |
WO2002077183A2 (en) | 2001-03-21 | 2002-10-03 | Elitra Pharmaceuticals, Inc. | Identification of essential genes in microorganisms |
GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
GB0108079D0 (en) | 2001-03-30 | 2001-05-23 | Microbial Technics Ltd | Protein |
WO2002094851A2 (en) | 2001-05-18 | 2002-11-28 | The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Healthand Human Services, Centers For Disease Control And Prevention, Technology Transfer Office | Peptide vaccines against group a streptococci |
AU2002322127B2 (en) | 2001-06-15 | 2008-08-21 | Inhibitex, Inc. | Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus |
CA2808598A1 (en) | 2001-08-02 | 2003-02-13 | University Of Sheffield | Antigenic polypeptides |
ES2386386T3 (es) | 2001-12-12 | 2012-08-20 | Novartis Vaccines And Diagnostics S.R.L. | Inmunización contra Chlamydia trachomatis |
US6525028B1 (en) | 2002-02-04 | 2003-02-25 | Corixa Corporation | Immunoeffector compounds |
US6911434B2 (en) | 2002-02-04 | 2005-06-28 | Corixa Corporation | Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds |
GB0203403D0 (en) | 2002-02-13 | 2002-04-03 | Chiron Spa | Chlamydia cytotoxic-T cell epitopes |
EP2275126A3 (en) | 2002-04-02 | 2011-04-27 | Ben-Gurion University Of The Negev Research And Development Authority | Protein-based streptococcus pneumoniae vaccines |
GB0210128D0 (en) | 2002-05-02 | 2002-06-12 | Chiron Spa | Nucleic acids and proteins from streptococcus groups A & B |
WO2003094850A2 (en) | 2002-05-09 | 2003-11-20 | Biomira, Inc. | Lipid a and other carbohydrate ligand analogs |
CA2487831A1 (en) | 2002-06-11 | 2003-12-18 | Glaxosmithkline Biologicals S.A. | Immunogenic compositions |
MXPA05000407A (es) | 2002-07-08 | 2005-04-19 | Corixa Corp | Procedimientos para la produccion de fosfato de aminoalquilglucosaminida e inmunoefectores de disacarido, e intermediarios para los mismos. |
US7288640B2 (en) | 2002-07-08 | 2007-10-30 | Corixa Corporation | Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor |
EP1551357B1 (en) | 2002-09-13 | 2014-07-16 | Novartis Vaccines and Diagnostics, Inc. | Group b streptococcus vaccine |
US7960522B2 (en) | 2003-01-06 | 2011-06-14 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
WO2004092360A2 (en) | 2003-04-10 | 2004-10-28 | Chiron Corporation | The severe acute respiratory syndrome coronavirus |
EP2311989A1 (en) | 2003-04-15 | 2011-04-20 | Intercell AG | S. pneumoniae antigens |
RU2352356C2 (ru) | 2003-06-26 | 2009-04-20 | Новартис Вэксинес Энд Дайэгностикс, Инк. | ИММУНОГЕННАЯ КОМПОЗИЦИЯ НА ОСНОВЕ АНТИГЕНА Chlamydia trachomatis (ВАРИАНТЫ) И ЕЕ ИСПОЛЬЗОВАНИЕ |
JP4875490B2 (ja) | 2003-07-31 | 2012-02-15 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | StreptococcusPyogenesについての免疫原組成物 |
US20070134263A1 (en) | 2004-02-18 | 2007-06-14 | Anderson Annaliesa S | Polypeptides for inducing a protective immune response against staphyloococcus aureus |
MX2007003402A (es) | 2004-09-22 | 2007-05-10 | Glaxosmithkline Biolog Sa | Composicion inmunogena para su uso en vacunacion contra estafilococos. |
JPWO2007004705A1 (ja) * | 2005-07-01 | 2009-01-29 | 国立精神・神経センター総長 | 糖脂質誘導体及びそれを有効成分とする治療剤 |
US7442511B2 (en) | 2005-12-27 | 2008-10-28 | Obetech, Llc | Adipogenic adenoviruses as a biomarker for disease |
US20090317421A1 (en) | 2006-01-18 | 2009-12-24 | Dominique Missiakas | Compositions and methods related to staphylococcal bacterium proteins |
CA2642721A1 (en) | 2006-02-17 | 2007-10-18 | Novartis Ag | Purification of bacterial antigens |
AR060187A1 (es) | 2006-03-30 | 2008-05-28 | Glaxosmithkline Biolog Sa | Composicion inmunogenica |
BRPI0710210A2 (pt) | 2006-03-30 | 2011-05-24 | Glaxomithkline Biolog S A | composição imunogênica, vacina, métodos para preparar a vacina, e para prevenir ou tratar infecção estafilocócica, uso da composição imunogênica, e, processo para conjugar oligassacarìdeo ou polissacarìdeo capsular |
HUE037808T2 (hu) | 2006-09-26 | 2018-09-28 | Infectious Disease Res Inst | Szintetikus adalékanyagot tartalmazó vakcina kompozíció |
EP2134349A1 (en) | 2007-04-19 | 2009-12-23 | Université Libre de Bruxelles | Aminoalkyl glucosamine phosphate compounds for treating autoimmune diseases |
AU2009234156A1 (en) * | 2008-04-09 | 2009-10-15 | The University Of North Carolina At Chapel Hill | Methods of regulating actin cytoskeletal rearrangement and intercellular gap formation |
US20120064044A1 (en) | 2009-04-09 | 2012-03-15 | Thomas Michael Egan | Methods of treating edema related to ischemia-reperfusion |
BRPI1011072B1 (pt) | 2009-06-05 | 2021-09-28 | Infectious Disease Research Institute | Composto de gla, composições de vacina e farmacêutica compreendendo dito composto, bem como uso dos mesmos para estimular, induzir ou acentuar uma resposta imune em um indivíduo |
RS58868B1 (sr) | 2012-02-07 | 2019-08-30 | Infectious Disease Res Inst | Poboljšane adjuvansne formulacije koje sadrže agoniste tlr4 i postupci upotrebe istih |
US20150125486A1 (en) | 2012-03-08 | 2015-05-07 | Novartis Ag | Adjuvanted formulations of pediatric antigens |
ES2743465T3 (es) | 2013-03-15 | 2020-02-19 | Glaxosmithkline Biologicals Sa | Composición que contiene derivados fosfato de aminoalquil glucosaminida tamponados y su uso para potenciar una respuesta inmunitaria |
EP3116480A1 (en) | 2014-03-12 | 2017-01-18 | GlaxoSmithKline Biologicals S.A. | Immunogenic liposomal formulation |
BE1022346A9 (fr) | 2014-03-12 | 2016-10-07 | Glaxosmithkline Biologicals Sa | Compositions liposomales pour une administration mucosale |
CA2972635A1 (en) | 2015-01-06 | 2016-07-14 | Immunovaccine Technologies Inc. | Lipid a mimics, methods of preparation, and uses thereof |
US10765690B2 (en) | 2015-08-06 | 2020-09-08 | Glaxosmithkline Intellectual Property Development Limited | TLR4 agonists and compositions thereof and their use in the treatment of cancer |
GB201612652D0 (en) | 2016-07-21 | 2016-09-07 | Takeda Pharmaceuticals Co | Novel compound |
-
2019
- 2019-02-12 MX MX2020008417A patent/MX2020008417A/es unknown
- 2019-02-12 BR BR112020016314-7A patent/BR112020016314A2/pt unknown
- 2019-02-12 SG SG11202007688YA patent/SG11202007688YA/en unknown
- 2019-02-12 CA CA3090271A patent/CA3090271A1/en active Pending
- 2019-02-12 EA EA202091931A patent/EA202091931A1/ru unknown
- 2019-02-12 US US16/968,835 patent/US11458151B2/en active Active
- 2019-02-12 AU AU2019218978A patent/AU2019218978A1/en active Pending
- 2019-02-12 EP EP19751710.5A patent/EP3752182B1/en active Active
- 2019-02-12 JP JP2020564809A patent/JP7362667B2/ja active Active
- 2019-02-12 WO PCT/US2019/017669 patent/WO2019157509A1/en unknown
- 2019-02-12 KR KR1020207026255A patent/KR20200123436A/ko not_active Application Discontinuation
- 2019-02-12 IL IL276608A patent/IL276608B2/en unknown
-
2022
- 2022-08-29 US US17/898,165 patent/US20230055805A1/en active Pending
-
2023
- 2023-10-04 JP JP2023172470A patent/JP2024001142A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230055805A1 (en) | 2023-02-23 |
IL276608B1 (en) | 2023-12-01 |
MX2020008417A (es) | 2020-11-11 |
JP7362667B2 (ja) | 2023-10-17 |
EP3752182B1 (en) | 2024-05-15 |
CN111867623A (zh) | 2020-10-30 |
CA3090271A1 (en) | 2019-08-15 |
BR112020016314A2 (pt) | 2020-12-15 |
JP2024001142A (ja) | 2024-01-09 |
IL276608A (en) | 2020-09-30 |
WO2019157509A1 (en) | 2019-08-15 |
US11458151B2 (en) | 2022-10-04 |
AU2019218978A1 (en) | 2020-09-03 |
JP2021512963A (ja) | 2021-05-20 |
IL276608B2 (en) | 2024-04-01 |
EP3752182A1 (en) | 2020-12-23 |
EA202091931A1 (ru) | 2020-11-05 |
US20210023106A1 (en) | 2021-01-28 |
EP3752182A4 (en) | 2021-12-01 |
KR20200123436A (ko) | 2020-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL268517A (en) | Anti-tigit antibodies | |
HK1257776A1 (zh) | 包含toll-樣受體激動劑的抗體綴合物 | |
ZA201905966B (en) | Anti-lag3 antibodies | |
IL272227A (en) | ANTI-TIGIT antibodies | |
ZA201906358B (en) | Improved antigen binding receptors | |
GB201709808D0 (en) | Antibodies | |
HK1253695A1 (zh) | T細胞受體特異性抗體 | |
IL274025A (en) | A new T-cell receptor | |
SG10201914130VA (en) | GARP-TGF-β ANTIBODIES | |
IL276608A (en) | TOLL-like receptor ligands | |
SG11202002489YA (en) | Anti-transthyretin antibodies | |
GB201720970D0 (en) | Antibodies | |
IL275187A (en) | Anti-alpha-synuclein antibodies | |
GB201702617D0 (en) | Receptor | |
IL271067A (en) | Anti-trkb antibodies | |
GB201711785D0 (en) | Antibodies | |
GB201701887D0 (en) | Receptor | |
GB201700926D0 (en) | Receptor | |
GB201717006D0 (en) | Anti-OPG antibodies | |
GB201709818D0 (en) | Antibodies | |
GB201703071D0 (en) | Antibodies | |
GB201701416D0 (en) | Anti-OPG antibodies |